Default company panoramic image


Clincally demonstrated, patented technology that solves problems undermining topical ophthalmic drug delivery, a $5+ billion market

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Andover, MA, USA
  • Currency USD
  • Founded January 2010
  • Employees 4
  • Website

Company Summary

Amorphex has developed a soft non-invasive device, TODDD™ to provide sustained drug delivery to the ocular surface. Comfortably concealed under the eyelid, one TODDD can deliver therapeutic levels of drug 24/7 over many months. Its polymer chemistry can incorporate a wide range of drugs. TODDD provides inherent compliance while avoiding the significant difficulties and side effects associated with eye drop delivery.


  • Default avatar
    Robert F. Thompson
    President & CEO

    - Former president of two Bausch & Lomb divisions (corporate officer)
    - 25+ years of global marketing expertise
    - Extensive new product launch experience
    - In depth executive management of corporate and start-up ophthalmic product development

  • Default avatar
    Charles E. Leahy, O.D., M.S.
    Founder, VP Clinical Affairs

    - Practicing clinician - Massachusetts Eye and Ear Infirmary
    - New product development experience with B&L
    - Extensive ophthalmic pharmaceutical development clinical testing experience
    - Instructor in Ophthalmology at Mass. Eye and Ear Infirmary, Harvard Medical School

  • Default avatar
    Edward J. Ellis, Ph.D.
    Founder, VP Science and Technology

    - Former Sr. VP science & technology at B&L
    - A founder of Polymer Technology (sold to B&L)
    - 30+ patents
    - Inventor and developer of numerous commercialized products ($2+Billion in sales)
    - Expertise in polymers and plastics


  • Default avatar
    Thomas Brady

Previous Investors

  • Default avatar
    Other support ($1.3 million)